Consolidated Investment Group’s Emergent Biosolutions EBS Stock Holding History

Consolidated Investment Group’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-18,200	Closed	-$1.88M	–	73
2020 Q3	$1.88M	Hold	18,200	–	–	0.63%	47
2020 Q2	$1.44M	Sell	18,200 -18,800	-51%	-$1.4M	0.54%	46
2020 Q1	$2.14M	Hold	37,000	–	–	0.95%	31
2019 Q4	$2M	Hold	37,000	–	–	0.94%	32
2019 Q3	$1.93M	Sell	37,000 -28,000	-43%	-$1.3M	1%	33
2019 Q2	$3.14M	Hold	65,000	–	–	1.64%	25
2019 Q1	$3.28M	Hold	65,000	–	–	1.64%	23
2018 Q4	$3.85M	Hold	65,000	–	–	1.97%	19
2018 Q3	$4.28M	Hold	65,000	–	–	2%	19
2018 Q2	$3.28M	Hold	65,000	–	–	1.59%	27
2018 Q1	$3.42M	Buy	+65,000	New	+$3.24M	1.66%	24

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Consolidated Investment Group's EBS Position: Q4 2020 in Review

Consolidated Investment Group sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 18,200 shares — an estimated $1.88M sold.

Consolidated Investment Group first reported a position in EBS in Q1 2018 and held it in 11 quarters. The position peaked at $4.28M in Q3 2018. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

Consolidated Investment Group reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
Consolidated Investment Group sold 18,200 Emergent Biosolutions shares in Q4 2020, an estimated $1.88M.
Consolidated Investment Group first reported a position in Emergent Biosolutions in Q1 2018 and held it in 11 quarters.
Consolidated Investment Group's Emergent Biosolutions position peaked at $4.28M in Q3 2018.
353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Consolidated Investment Group's 13F filing for Q4 2020, filed 19 Jan 2021.